Work

Oral APX3330 treatment reduces L-CNV lesions in preclinical mouse model and confirms Phase 2 DR/DME clinical dose with sufficient distribution to human retina using PBPK modeling

Year: 2021

Type: article

Source: Investigative Ophthalmology & Visual Science

Authors: Larissa Lachi Silva, Nathan Lambert-Cheatham, Robert E. Stratford, Sara K. Quinney, Timothy W. Corson, Mark R. Kelley

Institutions: Indiana University School of Medicine, Michigan State University

Language: English

Topic: Retinal Diseases and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,850

OpenAlex ID: W3186315985

FWCI: 0.898

Cites:

Cited by: 4

Related to: 10